CD274 and non-small cell lung carcinoma: Phase III clinical trial of durvalumab has reported that those NSCLC patients who are unable to apply tumor resection surgically and with PD-L1 ≥25% using durvalumab after radiotherapy obtain significantly better prognosis than those receiving radiotherapy alone 27.